U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 21:37:26 GMT 2025
Edited
by admin
on Mon Mar 31 21:37:26 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
66DDF797LP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OATP-8
Common Name English
LIVER-SPECIFIC ORGANIC ANION TRANSPORTER 2
Preferred Name English
OATP-1B3
Common Name English
LST2
Common Name English
OATP8
Common Name English
SLC21A8
Common Name English
LST3
Common Name English
SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B3
Common Name English
OATP1B3
Common Name English
LST-3TM13
Common Name English
SLCO1B3
Common Name English
Classification Tree Code System Code
UCSF-FDA TRANSPORTAL SLCO1B3
Created by admin on Mon Mar 31 21:37:26 GMT 2025 , Edited by admin on Mon Mar 31 21:37:26 GMT 2025
Code System Code Type Description
FDA UNII
66DDF797LP
Created by admin on Mon Mar 31 21:37:26 GMT 2025 , Edited by admin on Mon Mar 31 21:37:26 GMT 2025
PRIMARY
WIKIPEDIA
Solute_carrier_organic_anion_transporter_family_member_1B3
Created by admin on Mon Mar 31 21:37:26 GMT 2025 , Edited by admin on Mon Mar 31 21:37:26 GMT 2025
PRIMARY
From To
1_459 1_485
1_463 1_474
1_465 1_489
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_134
N 1_145
N 1_151
N 1_445
N 1_503
N 1_516
Related Record Type Details
Structure of VOXILAPREVIR
INHIBITOR -> TRANSPORTER
IC50
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
INHIBITOR -> TRANSPORTER
IC50
Structure of REPAGLINIDE
INHIBITOR -> TRANSPORTER
Structure of FEXOFENADINE
INHIBITOR -> TRANSPORTER
Structure of GEFITINIB
SUBSTRATE -> TRANSPORTER
Structure of PASIREOTIDE
NON-SUBSTRATE -> TRANSPORTER
Structure of BMS-962212
SUBSTRATE -> TRANSPORTER
Structure of Lurbinectedin
INHIBITOR -> TRANSPORTER
Structure of AMPRENAVIR
INHIBITOR -> TRANSPORTER
Structure of Digoxin
INHIBITOR -> TRANSPORTER
Structure of (2S,3S,4S,5R,6S)-6-((E)-((3-BROMO-4-FLUORO-ANILINO)-(4-(2-(SULFAMOYLAMINO)ETHYLAMINO)-1,2,5-OXADIAZOL-3-YL)METHYLENE)AMINO)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID
SUBSTRATE -> TRANSPORTER
Structure of ROSIGLITAZONE
INHIBITOR -> TRANSPORTER
Structure of REMDESIVIR
INHIBITOR -> TRANSPORTER
Structure of Guretolimod
SUBSTRATE -> TRANSPORTER
Structure of THRX-195518
SUBSTRATE -> TRANSPORTER
Coordination with OATP1B3 inhibitors (e.g. rifampicin, cyclosporine, etc.) could lead to an increase in systemic exposure of the active metabolite.
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
SUBSTRATE -> TRANSPORTER
HUMAN LIVER
TISSUE EXPRESSION->TRANSPORTER
Structure of PANOBINOSTAT
INHIBITOR -> TRANSPORTER
Structure of ELAGOLIX
INHIBITOR -> TRANSPORTER
Structure of IPTACOPAN
SUBSTRATE -> TRANSPORTER
Structure of LOPINAVIR
INHIBITOR -> TRANSPORTER
Structure of 25OHD3-3-O-GLUCURONIDE
SUBSTRATE -> TRANSPORTER
Structure of Resmetirom
INHIBITOR -> TRANSPORTER
Structure of REGORAFENIB ANHYDROUS
SUBSTRATE -> TRANSPORTER
Structure of Tirbanibulin
INHIBITOR -> TRANSPORTER
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by OATP1B3
IC50
Structure of TENOFOVIR ALAFENAMIDE
SUBSTRATE -> TRANSPORTER
Structure of ELISMETREP
NON-SUBSTRATE -> TRANSPORTER
Structure of SIMEPREVIR
SUBSTRATE -> TRANSPORTER
Structure of RHINACANTHIN C
INHIBITOR -> TRANSPORTER
IC50
Structure of TECHNETIUM TC-99M MEBROFENIN
SUBSTRATE -> TRANSPORTER
MEB (80 pM) transport by OATP1B1 and OATP1B3 was inhibited by rifampicin (50 ?M) to 4% of control
Structure of MK-571
INHIBITOR -> TRANSPORTER
Structure of SAQUINAVIR
INHIBITOR -> TRANSPORTER
Structure of PENICILLIN G
INHIBITOR -> TRANSPORTER
Structure of RITONAVIR
INHIBITOR -> TRANSPORTER
Structure of Selexipag
INHIBITOR -> TRANSPORTER
IC50
Structure of PROBENECID
INHIBITOR -> TRANSPORTER
Structure of SULFOBROMOPHTHALEIN SODIUM
INHIBITOR -> TRANSPORTER
Structure of LONAFARNIB
INHIBITOR -> TRANSPORTER
Structure of AZELAPRAG
SUBSTRATE -> TRANSPORTER
Structure of Nilotinib
SUBSTRATE -> TRANSPORTER
Structure of ELBASVIR
INHIBITOR -> TRANSPORTER
IC50
Structure of VANDETANIB
SUBSTRATE -> TRANSPORTER
Structure of OPICAPONE
SUBSTRATE -> TRANSPORTER
Structure of VELPATASVIR
SUBSTRATE -> TRANSPORTER
IC50
Structure of DUVELISIB
INHIBITOR -> TRANSPORTER
Structure of Cyclosporine
INHIBITOR -> TRANSPORTER
substrate used: Amantinin, Bosentan, Bromsulphthalein (BSP), Rosuvastatin
Structure of MIFEPRISTONE
INHIBITOR -> TRANSPORTER
Structure of PRAVASTATIN
SUBSTRATE -> TRANSPORTER
Structure of DASATINIB
SUBSTRATE -> TRANSPORTER
Structure of Laselipag
INHIBITOR -> TRANSPORTER
IC50
Structure of GS-563117
INHIBITOR -> TRANSPORTER
IN VITRO
Structure of ELIMUSERTIB
INHIBITOR -> TRANSPORTER
Structure of Digoxin
SUBSTRATE -> TRANSPORTER
Structure of SILDENAFIL
INHIBITOR -> TRANSPORTER
Structure of ESTRONE SULFATE
INHIBITOR -> TRANSPORTER
Structure of BRANEBRUTINIB
INHIBITOR -> TRANSPORTER
Structure of Selexipag
SUBSTRATE -> TRANSPORTER
SILIBININ
INHIBITOR -> TRANSPORTER
Structure of BILIRUBIN
SUBSTRATE -> TRANSPORTER
Structure of BQ-123
SUBSTRATE -> TRANSPORTER
Structure of 25-HYDROXYVITAMIN D3 3.BETA.-SULFATE
SUBSTRATE -> TRANSPORTER
Structure of OPICAPONE
INHIBITOR -> TRANSPORTER
IC50
Structure of PREDNISOLONE 21-PHOSPHATE
INHIBITOR -> TRANSPORTER
Structure of LETERMOVIR
INHIBITOR -> TRANSPORTER
Structure of PACLITAXEL
SUBSTRATE -> TRANSPORTER
Structure of Digoxin
SUBSTRATE -> TRANSPORTER
Structure of GRAZOPREVIR ANHYDROUS
SUBSTRATE -> TRANSPORTER
Structure of Rifamycin
INHIBITOR -> TRANSPORTER
Structure of FEVIPIPRANT
SUBSTRATE -> TRANSPORTER
Structure of METHOTREXATE
SUBSTRATE -> TRANSPORTER
Structure of GRAZOPREVIR ANHYDROUS
INHIBITOR -> TRANSPORTER
IC50
Structure of Pralsetinib
INHIBITOR -> TRANSPORTER
Structure of DABRAFENIB
INHIBITOR -> TRANSPORTER
Structure of DARUNAVIR
INHIBITOR -> TRANSPORTER
Structure of ENCORAFENIB
INHIBITOR -> TRANSPORTER
IC50
TROGLITAZONE
INHIBITOR -> TRANSPORTER
Structure of LETERMOVIR
SUBSTRATE -> TRANSPORTER
Structure of MONTELUKAST
INHIBITOR -> TRANSPORTER
Structure of SELINEXOR
INHIBITOR -> TRANSPORTER
In vitro, selinexor inhibits OATP1B3 with an IC50 value of 6.20 ?M.
IC50
Structure of IDELALISIB
INHIBITOR -> TRANSPORTER
Structure of INDINAVIR
INHIBITOR -> TRANSPORTER
Structure of PF-04991532
SUBSTRATE -> TRANSPORTER
Structure of GLECAPREVIR
SUBSTRATE -> TRANSPORTER
Structure of BRILANESTRANT
INHIBITOR -> TRANSPORTER
Ki
Structure of Atazanavir
INHIBITOR -> TRANSPORTER
substrate used: Cholyl-glycylamido-fluorescein (CGamF)
Structure of ATRASENTAN
SUBSTRATE -> TRANSPORTER
Structure of Voclosporin
INHIBITOR -> TRANSPORTER
IN VITRO
Structure of VOXILAPREVIR
SUBSTRATE -> TRANSPORTER
Structure of Resmetirom
SUBSTRATE -> TRANSPORTER
Structure of GLECAPREVIR
INHIBITOR -> TRANSPORTER
Structure of PACLITAXEL
INHIBITOR -> TRANSPORTER
Structure of RIFAMPIN
SUBSTRATE -> TRANSPORTER
Structure of ELISMETREP
INHIBITOR -> TRANSPORTER
Structure of TEMSAVIR
INHIBITOR -> TRANSPORTER
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966